A homogeneous enzyme immunoassay reagent for vanillylmandelic acid based on brominated derivatives and a preparation method thereof

Through the vanilla mandelic acid homogeneous enzyme immunoassay reagent based on brominated derivatives, combined with a fully automatic biochemical analyzer, the problem of insufficient sensitivity and specificity of vanilla mandelic acid detection in the prior art is solved, and efficient and accurate micro-quantity Vanilla mandelic acid test, suitable for clinical use.

CN114354938BActive Publication Date: 2024-11-29SUZHOU EVERMED BIOMEDICAL CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202210004392.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-01-05
Publication Date
2024-11-29
Estimated Expiration
2042-01-05

AI Technical Summary

Technical Problem

The existing vanilla mandelic acid detection methods are cumbersome to operate, have poor accuracy, insufficient sensitivity and specificity, and cannot meet the needs of clinical testing, especially the detection of trace VMA.

Method used

Develop a vanilla mandelic acid homogeneous enzyme immunoassay reagent based on brominated derivatives, using a combination of R1 and R2 reagents, containing anti-vanilla mandelic acid specific antibodies and vanilla mandelic acid brominated derivative enzyme label conjugate, The detection is carried out through a fully automatic biochemical analyzer to achieve high-throughput and rapid determination of trace vanilla mandelic acid content.

Benefits of technology

This method improves the sensitivity and specificity of vanilla mandelic acid detection, can accurately detect trace amounts of vanilla mandelic acid in biological samples, reduces the detection cost, and is suitable for widespread clinical promotion.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114354938B_ABST
    Figure CN114354938B_ABST
Patent Text Reader

Abstract

The present invention relates to a vanillylmandelic acid homogeneous enzyme immunoassay reagent based on brominated derivatives and a preparation method thereof. The vanillylmandelic acid brominated derivatives and the synthesis method are targeted new research and design. The vanillylmandelic acid brominated derivative immunogen prepared by using the newly developed vanillylmandelic acid brominated derivatives, and the anti-vanillylmandelic acid specific antibody prepared by immunizing experimental animals with the vanillylmandelic acid brominated derivative immunogen have no cross reaction with 30 common hormones and hormone metabolites. The vanillylmandelic acid homogeneous enzyme immunoassay reagent based on brominated derivatives prepared by using the above-mentioned anti-vanillylmandelic acid specific antibody and the vanillylmandelic acid brominated derivative enzyme-labeled conjugate has a detection sensitivity of ng / mL level, can accurately detect the concentration of trace vanillylmandelic acid in biological samples, and its detection accuracy, precision, sensitivity and specificity are significantly higher than the prior art.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biological detection, and in particular relates to a vanillylmandelic acid homogeneous enzyme immunoassay reagent based on brominated derivatives and a preparation method thereof. Background Art

[0002] Vanillymandelic Acid (VMA) has a structural formula as shown in Formula IV:

[0003]

[0004] Formula IV.

[0005] Vanillylmandelic acid, also known as 3-methoxy-4-hydroxymandelic acid (DL-3-Methoxy-4-hydroxymandelic acid, MHMA) or vanillylmandelic acid, is the terminal metabolite of adrenal medullary hormone catecholamine (CA) substances. Almost all CA is metabolized in the body. A small part of CA is converted into p-dihydroxymandelic acid by monoamine oxidase, and most of CA is converted into 3-methoxyepinephrine or norepinephrine by CA-O-methyltransferase, and finally metabolized into 3-methoxy-4-hydroxymandelic acid. CA metabolism in the body is very rapid, and its metabolites are mostly excreted in urine. Clinically, the increase of VMA content in 24h urine is seen in pheochromocytoma, neuroblastoma, primary hypertension, myocardial infarction, chronic renal insufficiency, hyperthyroidism or hypothyroidism, adrenal cortex insufficiency, sympathetic nerve physiological function abnormalities, etc. Therefore, the determination of the excretion of VMA in 24h urine is of great significance for the clinical diagnosis of the above diseases.

[0006] The classic VMA detection methods mainly include: visible light spectrophotometry, which has a cumbersome operation process and poor precision; gas chromatography, which has high requirements for instruments and is complex to operate; high-phase liquid-electrochemical method, which is easily disturbed by instrument quality and working environment, and the sensitivity and specificity of the determination need to be further improved; diazo method, which has cumbersome operation and low reliability, and the recovery rate, repeatability and stability need to be improved. None of the above determination methods can meet the needs of VMA clinical testing. At present, there is a lack of VMA detection reagents with good stability, high sensitivity and strong specificity on the market, especially fully automated detection reagents that can accurately determine the trace VMA content in biological samples. Therefore, the development of a VMA detection reagent that meets the quality requirements of clinical testing, is highly practical, and has high cost performance, and can be applied to fully automatic biochemical analyzers has become a research hotspot in this field. Summary of the invention

[0007] The technical problem to be solved by the present invention is: in view of the above-mentioned defects of the prior art, a vanillylmandelic acid homogeneous enzyme immunoassay reagent based on brominated derivatives which is easy to use, highly sensitive and highly specific and a preparation method thereof are provided. The vanillylmandelic acid homogeneous enzyme immunoassay reagent based on brominated derivatives can realize the fully automated determination of the content of vanillylmandelic acid on a fully automatic biochemical analyzer, and can determine the content of trace vanillylmandelic acid in biological samples in a high-throughput, rapid and accurate manner, and has the advantages of simple operation, high sensitivity, strong specificity, accurate results, etc., effectively reducing the cost of vanillylmandelic acid detection, and is conducive to the widespread promotion and use in clinical practice.

[0008] The technical solution adopted by the present invention to solve its technical problem is: providing a brominated derivative-based vanillylmandelic acid homogeneous enzyme immunoassay reagent, including R1 reagent and R2 reagent, wherein the R1 reagent contains an anti-vanillylmandelic acid specific antibody and a homogeneous enzyme substrate solution; the R2 reagent contains a vanillylmandelic acid brominated derivative enzyme-labeled conjugate and an R2 buffer.

[0009] The anti-vanillylmandelic acid specific antibody is produced by immunizing an experimental animal with a brominated vanillylmandelic acid derivative immunogen, and the experimental animal is one of rabbits, goats, sheep, rats, mice, guinea pigs or horses; preferably, the experimental animal is a rabbit.

[0010] The vanillylmandelic acid bromide derivative immunogen is formed by connecting the vanillylmandelic acid bromide derivative with a carrier, and its structural formula is shown in the following formula (I):

[0011]

[0012] Formula (I);

[0013] The carrier is an immunogenic protein or polypeptide, selected from serum protein, ovalbumin, gamma globulin, thyroglobulin, hemocyanin or poly-lysine; preferably, the carrier is serum protein; more preferably, the carrier is bovine serum albumin.

[0014] The vanillylmandelic acid bromide derivative enzyme-labeled conjugate is formed by connecting the vanillylmandelic acid bromide derivative with artificially mutated glucose-6-phosphate dehydrogenase (mG6PDH), and its structural formula is shown in the following formula (II):

[0015]

[0016] Formula (II).

[0017] In the formula, mG6PDH is artificially mutated glucose-6-phosphate dehydrogenase, and the amino acid sequence of the artificially mutated glucose-6-phosphate dehydrogenase is SEQ ID NO: 1;

[0018] Specifically, the amino acid sequence of the artificially mutated glucose-6-phosphate dehydrogenase (SEQ ID NO: 1) is as follows:

[0019] MGSAASLPPQATQVSFSKADFEELLHVVDTSQKNVKEALGKAGIALGEAPKQQPAPSAASICLEQEAWRSGKLSVTVLGATGCLAKKETFPALLDLFAHDYLQHEAVIVCFARKSMTTEDFRAYLSEALAKSHVCQCMPEVRDSI PAFLKKVHYCAGAYDSVEAMTELDKLLTVEEERFHLDDNDAPKKQSFRIFYFAIPPFVFQGAAKAIKEVAMAKDGSTRLIIEKPFGHDLTSAQELQECLSALFKEEEIYRMDHFLGYEICQNILSVRFGNQFLEPLMNNKHVAAVR VTLKECFGTEGRGGYFTKYGIIRDVIQNHLLQMLCLVAMERPGDMDWEADVRDRKVELLKAMEPFDPSSVVLGQYVGAKGKPGYLEDDSITEADRDMAKKCPTFCQMVVRINNERWQCVNFIVRAGKAIDECKCEIRVQFKEAECC GKLFGEQYPARNELVLRVSPGEAIYMKMSVKSPGLSKQLMQSEMDLSYSVRYPGIYCPSAYTRLILAGIRGQSESFVRCDELMRSWELFTPFLEKIADWQPKPYGSRGPAVACEALELYGYQKPEGYCWRPPHQPPALTRLMTR

[0020] The vanillylmandelic acid bromide derivative has a structural formula as shown in the following formula (III):

[0021]

[0022] Formula (III).

[0023] The preparation method of the vanillylmandelic acid homogeneous enzyme immunoassay reagent based on brominated derivatives of the present invention comprises the following steps:

[0024] (S1.1) Preparation of R1 reagent: 6.0% oxidized nicotinamide adenine dinucleotide, 6.0% glucose-6-phosphate, 0.3% bovine serum albumin, and 0.03% NaN3 are dissolved in a Tris buffer with a concentration of 60 mmol / L and pH=7.8 to prepare a homogeneous enzyme substrate solution; then, anti-vanillylmandelic acid specific antibody is added to the homogeneous enzyme substrate solution and mixed to obtain R1 reagent, wherein the volume ratio of the anti-vanillylmandelic acid specific antibody to the homogeneous enzyme substrate solution is 1:50 to 1:5000. Preferably, the volume ratio of the anti-vanillylmandelic acid specific antibody to the homogeneous enzyme substrate solution is 1:625.

[0025] (S1.2) Preparation of R2 reagent: 0.3% of bovine serum albumin and 0.03% of NaN3 are dissolved in a Tris buffer with a concentration of 150 mmol / L and pH=8.0 to prepare R2 buffer, and then the vanillylmandelic acid bromide derivative enzyme-labeled conjugate is added to the R2 buffer and mixed to obtain R2 reagent, wherein the volume ratio of the vanillylmandelic acid bromide derivative enzyme-labeled conjugate to the R2 buffer is 1:50 to 1:5000. Preferably, the volume ratio of the vanillylmandelic acid bromide derivative enzyme-labeled conjugate to the R2 buffer is 1:1250.

[0026] Wherein, the method for preparing the anti-vanillylmandelic acid specific antibody comprises the following steps:

[0027] (S2.1) diluting the vanillylmandelic acid bromide derivative immunogen to 8.0 mg / ml with PBS buffer having a concentration of 10 mmol / L and a pH of 7.4 to obtain an artificial antigen solution, and then mixing 5.0 ml of the artificial antigen solution with an equal amount of Freund's complete adjuvant and injecting the solution into the experimental animals;

[0028] (S2.2) One week later, the artificial antigen solution described in step (S2.1) was diluted by half with PBS buffer having a concentration of 10 mmol / L and a pH of 7.4, and then 5.0 ml of the diluted artificial antigen solution was mixed with an equal amount of Freund's incomplete adjuvant and injected into the above experimental animals;

[0029] (S2.3) After that, the experimental animals are injected once every 4 weeks according to the method in step (S2.2), for a total of 5 injections, to strengthen immunity;

[0030] (S2.4) Blood is collected from the experimental animals after booster immunization, and the blood is separated and purified to obtain anti-vanillylmandelic acid specific antibodies.

[0031] The method for preparing the brominated vanillylmandelic acid derivative immunogen comprises the following steps:

[0032] (S3.1) dissolving 2.0% by mass of the carrier in 10.0 mmol / L sodium phosphate buffer at pH 8.0 to obtain a carrier solution;

[0033] (S3.2) dissolving 1.0% by mass of the brominated vanillylmandelic acid derivative, 3.0% of dimethylformamide, and 3.0% of ethanol in 8.0 mmol / L potassium phosphate buffer at pH 7.5 to obtain a mixed solution, and stirring the mixed solution gently at 0 to 4° C. for 60 to 90 minutes to obtain a brominated vanillylmandelic acid derivative solution;

[0034] (S3.3) The vanillylmandelic acid bromide derivative solution obtained in step (S3.2) is slowly added dropwise to the carrier solution obtained in step (S3.1), and then the reaction is stirred at 0-4°C for 12-24 hours to obtain a conjugate solution. 1.0 mmol / L ethylenediaminetetraacetic acid is added to the above conjugate solution, and then dialyzed and purified using 10.0 mmol / L HEPES buffer, pH=7.0. The solution obtained after purification is the vanillylmandelic acid bromide derivative immunogen solution. 0.05% by mass of NaN3 is added to the above vanillylmandelic acid bromide derivative immunogen solution, and stored at -20°C.

[0035] The preparation method of the vanillylmandelic acid bromide derivative enzyme-labeled conjugate comprises the following steps:

[0036] (S4.1) Dissolve 200KU artificially induced glucose-6-phosphate dehydrogenase at a mass fraction of 5.0% in a sodium phosphate buffer containing 50.0 mmol / L and a pH of 7.3 at room temperature; then add 1.0 mmol / L ethylenediaminetetraacetic acid; mix well and incubate at 4°C for 10 to 20 hours to obtain an artificially induced glucose-6-phosphate dehydrogenase solution;

[0037] (S4.2) Dissolving 1.5% by mass of the brominated vanillylmandelic acid derivative, 4.5% of dimethylformamide, and 4.5% of ethanol in an 8.0 mmol / L potassium phosphate buffer solution at pH 7.5 to obtain a mixed solution, and stirring the mixed solution gently at 0 to 4° C. for 60 to 120 minutes to obtain a brominated vanillylmandelic acid derivative solution;

[0038] (S4.3) The vanillylmandelic acid bromide derivative solution obtained in step (S4.2) is slowly added dropwise to the artificially induced glucose-6-phosphate dehydrogenase solution obtained in step (S4.1), and then the reaction is stirred at 0 to 4°C for 12 to 24 hours; the coupling product after the reaction is purified by a G-50 dextran gel chromatography column, and the solution obtained after purification is the vanillylmandelic acid bromide derivative enzyme-labeled conjugate solution, and 0.05% by mass of BSA and 0.05% by mass of NaN3 are added to the above-mentioned vanillylmandelic acid bromide derivative enzyme-labeled conjugate solution, and stored at 0 to 4°C.

[0039] The synthetic route of the brominated vanillylmandelic acid derivative represented by the above formula (III) is as follows:

[0040] .

[0041] The synthetic route of the brominated vanillylmandelic acid derivatives, the specific preparation steps are as follows:

[0042] (S5.1) Synthesis of compound 3:

[0043]

[0044] Compound 1 (10 g, 51 mmol) was weighed and dissolved in DMF (100 ml), and then DIEA (20 ml, 160 mmol), HATU (22 g, 60 mmol) and compound 2 (9.6 g, 60 mmol) were added to prepare a reaction mixture solution, and the reaction mixture solution was stirred at room temperature overnight; then purified water (200 mL) was added to the reaction mixture solution, and filtered; the filter cake obtained by filtration was dried in vacuum, and then purified by silica gel to obtain compound 3.

[0045] (S5.2) Synthesis of compound 4:

[0046]

[0047] Compound 3 (12 g, 35 mmol) was dissolved in 100 mL of DCM, and then 3,4-dihydro-2H-pyran (8.8 g, 105 mmol) and p-TosOH (0.3 g, 1.7 mmol) were added to prepare a reaction mixture solution, and the reaction mixture solution was stirred at room temperature for 24 hours; then the solvent was concentrated to obtain a crude product, and the crude product was purified by flash column chromatography (SiO2) to obtain compound 4.

[0048] (S5.3) Synthesis of compound 5:

[0049]

[0050] Compound 4 (5.1 g, 10 mmol) was weighed and dissolved in DCM (50 mL) at 0°C, and then 50 mL of TFA was added to prepare a reaction mixture solution; the reaction mixture solution was stirred at room temperature overnight, and then the solvent was removed by evaporation under reduced pressure, and purified by flash column chromatography (SiO2) to obtain compound 5.

[0051] (S5.4) Synthesis of compound 6:

[0052]

[0053] Compound 5 (4.1 g, 10 mmol) was weighed and dissolved in DCM (50 mL) at 0°C, and then TEA (2 g, 20 mmol) and bromoacetyl bromide (2.4 g, 12 mmol) were added to prepare a reaction mixture solution; the reaction mixture solution was stirred at room temperature overnight, and then the solvent was removed by evaporation under reduced pressure, and purified by flash column chromatography (SiO2) to obtain compound 6.

[0054] (S5.5) Synthesis of brominated vanillylmandelic acid derivatives:

[0055]

[0056] Compound 6 (2.6 g, 5 mmol) was weighed and dissolved in DCM (50 ml) at 0°C, and then HCl / MeOH (2N, 10 mL) was added to prepare a reaction mixture solution; the reaction mixture solution was stirred at room temperature overnight, and then the solvent was removed by evaporation under reduced pressure, and purified by flash column chromatography (SiO2) to obtain a vanillylmandelic acid bromide derivative.

[0057] The method for using the vanillylmandelic acid homogeneous enzyme immunoassay reagent based on brominated derivatives of the present invention comprises the following steps:

[0058] (S6.1) Add the sample to be tested and R1 reagent to the fully automatic biochemical analyzer, mix well, and incubate at 37°C for 3-5 minutes;

[0059] (S6.2) Add R2 reagent, mix well, keep constant temperature at 37°C for 5-10 minutes, detect at 340 nm, continuously monitor the absorbance change rate within 3 minutes, and automatically calculate the content of vanillylmandelic acid in the sample by a fully automatic biochemical analyzer;

[0060] Wherein, the sample to be tested is a physiological sample; preferably, the physiological sample is serum, plasma, urine, saliva; more preferably, the physiological sample is serum or plasma. The R1 reagent and the R2 reagent are used in a volume ratio of 1:1 to 4:1; preferably, they are used in a volume ratio of 4:1.

[0061] The beneficial effects of the present invention are:

[0062] 1. The brominated vanillylmandelic acid derivatives and synthesis methods described in the present invention are targeted new research and design and do not exist in the prior art.

[0063] 2. The vanillylmandelic acid bromide derivative immunogen prepared by the present invention using the newly developed vanillylmandelic acid bromide derivative has stronger immunogenicity than the conventional vanillylmandelic acid immunogen prepared in the prior art; the anti-vanillylmandelic acid specific antibody prepared by immunizing experimental animals with the vanillylmandelic acid bromide derivative immunogen has significantly improved specificity and sensitivity compared with the anti-vanillylmandelic acid specific antibody prepared in the prior art, and has no cross-reaction with 30 common hormones and hormone metabolites.

[0064] 3. The vanillylmandelic acid homogeneous enzyme immunoassay reagent based on brominated derivatives prepared by using the above-mentioned anti-vanillylmandelic acid specific antibody and the vanillylmandelic acid brominated derivative enzyme-labeled conjugate of the present invention has a detection sensitivity of ng / mL level, and can accurately detect the concentration of trace vanillylmandelic acid in biological samples; the detection reagent is easy to use, and can realize high-throughput and rapid detection of vanillylmandelic acid on a fully automatic biochemical analyzer, and its detection accuracy, precision, sensitivity and specificity are significantly higher than the existing technology; the detection reagent can also effectively reduce the detection cost of vanillylmandelic acid, which is conducive to clinical promotion and use. BRIEF DESCRIPTION OF THE DRAWINGS

[0065] Figure 1 is the standard curve of the vanillylmandelic acid ELISA detection method in Example 6;

[0066] Figure 2 is the standard curve of the homogeneous enzyme immunoassay method for vanillylmandelic acid in Example 7;

[0067] Figure 3 is a scatter plot of comparative experimental data of detecting vanillylmandelic acid by homogeneous enzyme immunoassay and high performance liquid chromatography in Example 9;

[0068] Figure 4 It is a brominated derivative of vanillylmandelic acid represented by formula (III) 1 H NMR spectral scanning analysis spectrum;

[0069] Figure 5This is the LC-MS analysis spectrum of the brominated vanillylmandelic acid derivative represented by formula (III). DETAILED DESCRIPTION

[0070] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments. These drawings are simplified schematic diagrams, which only illustrate the basic structure of the present invention in a schematic manner, so they only show the composition related to the present invention. Unless otherwise specified, the reagents, instruments, equipment, and consumables used in the following examples can be purchased from regular channels.

[0071] Example 1 Synthesis of brominated derivatives of vanillylmandelic acid

[0072] The chemical structure of the brominated derivative of vanillylmandelic acid is shown in formula (III):

[0073]

[0074] Formula (III).

[0075] The synthetic route of the above-mentioned vanillylmandelic acid bromide derivative is as follows:

[0076] .

[0077] The specific synthesis steps are as follows:

[0078] (1) Synthesis of compound 3:

[0079]

[0080] Compound 1 (10 g, 51 mmol) was weighed and dissolved in DMF (100 ml), and then DIEA (20 ml, 160 mmol), HATU (22 g, 60 mmol) and compound 2 (9.6 g, 60 mmol) were added to prepare a reaction mixture solution, and the reaction mixture solution was stirred at room temperature overnight; purified water (200 mL) was then added to the reaction mixture solution, and filtered; the filter cake obtained by filtration was dried in vacuum, and then purified by silica gel to obtain a white solid compound 3 (13 g) with a yield of 75%.

[0081] (2) Synthesis of compound 4:

[0082]

[0083] Compound 3 (12 g, 35 mmol) was dissolved in 100 mL of DCM, and then 3,4-dihydro-2H-pyran (8.8 g, 105 mmol) and p-TosOH (0.3 g, 1.7 mmol) were added to prepare a reaction mixture solution, and the reaction mixture solution was stirred at room temperature for 24 hours; then the solvent was concentrated to obtain a crude product, and the crude product was purified by flash column chromatography (SiO2) to obtain 9 g of compound 4, with a yield of 51%.

[0084] (3) Synthesis of compound 5:

[0085]

[0086] Compound 4 (5.1 g, 10 mmol) was weighed and dissolved in DCM (50 mL) at 0°C, and then 50 mL of TFA was added to prepare a reaction mixture solution; the reaction mixture solution was stirred at room temperature overnight, and then the solvent was removed by evaporation under reduced pressure and purified by flash column chromatography (SiO2) to obtain 3.6 g of compound 5 as a white solid. Yield: 88%.

[0087] (4) Synthesis of compound 6:

[0088]

[0089] Compound 5 (4.1 g, 10 mmol) was weighed and dissolved in DCM (50 mL) at 0°C, and then TEA (2 g, 20 mmol) and bromoacetyl bromide (2.4 g, 12 mmol) were added to prepare a reaction mixture solution; the reaction mixture solution was stirred at room temperature overnight, and then the solvent was removed by evaporation under reduced pressure and purified by flash column chromatography (SiO2) to obtain 3.4 g of compound 6 as a white solid. Yield: 64%.

[0090] (5) Synthesis of brominated vanillylmandelic acid derivatives:

[0091]

[0092] Compound 6 (2.6 g, 5 mmol) was weighed and dissolved in DCM (50 ml) at 0°C, and then HCl / MeOH (2N, 10 mL) was added to prepare a reaction mixture solution; the reaction mixture solution was stirred at room temperature overnight, and then the solvent was evaporated under reduced pressure and purified by flash column chromatography (SiO2) to obtain 0.9 g of vanillylmandelic acid bromide derivative as a yellow solid, with a yield of 50%.

[0093] The structure of the vanillylmandelic acid bromide derivative prepared in the above synthesis step was identified as follows: (1) The yellow solid compound was chromatographed using VARIAN MERCURY plus 400MHz. 1 H NMR spectroscopy scanning, using TMS as the internal standard; (2) LC-MS detection method: instrument Agilent 1200A, chromatographic column: C18; chromatographic column size: 4.6 *50mm; mobile phase: B (ACN), A (0.05% FA in water); gradient (B%): as Acq. above method.

[0094] It has been identified that the brominated vanillylmandelic acid derivative prepared by the above synthesis steps has a chemical structure shown in formula (III).

[0095] Example 2 Preparation of Brominated Vanillylmandelic Acid Derivative Immunogen

[0096] The vanillylmandelic acid bromide derivative immunogen in this embodiment is formed by linking the vanillylmandelic acid bromide derivative represented by formula (III) with bovine serum albumin (BSA), and its structural formula is shown in the following formula (I):

[0097]

[0098] Formula (I).

[0099] The method for synthesizing the vanillylmandelic acid bromide derivative immunogen comprises the following specific steps:

[0100] (S3.1) dissolving 2.0% by mass of the carrier in 10.0 mmol / L sodium phosphate buffer at pH 8.0 to obtain a carrier solution;

[0101] (S3.2) Dissolving 1.0% by mass of the brominated vanillylmandelic acid derivative, 3.0% by mass of dimethylformamide, and 3.0% by mass of ethanol in 8.0 mmol / L potassium phosphate buffer at pH 7.5 to obtain a mixed solution, and stirring the mixed solution gently at 0 to 4° C. for 75 minutes to obtain a brominated vanillylmandelic acid derivative solution;

[0102] (S3.3) The vanillylmandelic acid bromide derivative solution obtained in step (S3.2) is slowly added dropwise to the carrier solution obtained in step (S3.1), and then the reaction is stirred at 0-4°C for 18 hours to obtain a conjugate solution. 1.0 mmol / L ethylenediaminetetraacetic acid is added to the above conjugate solution, and then dialyzed and purified using 10.0 mmol / L HEPES buffer, pH=7.0. The solution obtained after purification is the vanillylmandelic acid bromide derivative immunogen solution. 0.05% by mass of NaN3 is added to the above vanillylmandelic acid bromide derivative immunogen solution, and stored at -20°C.

[0103] Example 3 Preparation of anti-vanillylmandelic acid specific antibodies

[0104] The vanillylmandelic acid bromide derivative immunogen prepared in Example 2 was made into an artificial antigen solution, and the experimental rabbit was inoculated by multi-point subcutaneous injection. After booster immunization, the antiserum was extracted and purified to obtain the antibody. The specific steps are as follows:

[0105] (1) using a PBS buffer solution with a concentration of 10 mmol / L and a pH of 7.4 to dilute the vanillylmandelic acid bromide derivative immunogen to 8.0 mg / ml to obtain an artificial antigen solution, and then mixing 5.0 ml of the artificial antigen solution with an equal amount of Freund's complete adjuvant and injecting the solution into an experimental rabbit;

[0106] (2) One week later, the artificial antigen solution described in step (1) was diluted by half with PBS buffer having a concentration of 10 mmol / L and a pH of 7.4, and then 5.0 ml of the diluted artificial antigen solution was mixed with an equal amount of Freund's incomplete adjuvant and injected into the above experimental rabbits;

[0107] (3) Thereafter, the experimental rabbits were injected once every four weeks according to the method in step (2), for a total of five injections, to strengthen immunity;

[0108] (4) Blood is collected from the experimental rabbits after booster immunization, and the blood is separated and purified to obtain anti-vanillylmandelic acid specific antibodies.

[0109] Example 4 Preparation of enzyme-labeled conjugates of brominated vanillylmandelic acid derivatives

[0110] The vanillylmandelic acid bromide derivative enzyme-labeled conjugate in this embodiment is formed by connecting the vanillylmandelic acid bromide derivative shown in formula (III) with artificially mutated glucose-6-phosphate dehydrogenase (mG6PDH), and its structural formula is shown in the following formula (II):

[0111]

[0112] Formula (II);

[0113] The method for synthesizing the vanillylmandelic acid bromide derivative enzyme-labeled conjugate comprises the following specific steps:

[0114] (S4.1) Dissolve 200KU artificially induced glucose-6-phosphate dehydrogenase at a mass fraction of 5.0% in a sodium phosphate buffer containing 50.0 mmol / L and a pH of 7.3 at room temperature; then add 1.0 mmol / L ethylenediaminetetraacetic acid; mix well and incubate at 4°C for 15 hours to obtain an artificially induced glucose-6-phosphate dehydrogenase solution;

[0115] (S4.2) Dissolving 1.5% by mass of the brominated vanillylmandelic acid derivative, 4.5% of dimethylformamide, and 4.5% of ethanol in an 8.0 mmol / L potassium phosphate buffer solution at pH 7.5 to obtain a mixed solution, and stirring the mixed solution gently at 0 to 4° C. for 90 minutes to obtain a brominated vanillylmandelic acid derivative solution;

[0116] (S4.3) The vanillylmandelic acid bromide derivative solution obtained in step (S4.2) is slowly added dropwise to the artificially induced glucose-6-phosphate dehydrogenase solution obtained in step (S4.1), and then stirred for reaction at 0-4°C for 18 hours; the coupling product after the reaction is purified by a G-50 dextran gel chromatography column, and the solution obtained after purification is the vanillylmandelic acid bromide derivative enzyme-labeled conjugate solution, and 0.05% by mass of BSA and 0.05% by mass of NaN3 are added to the above-mentioned vanillylmandelic acid bromide derivative enzyme-labeled conjugate solution, and stored at 0-4°C.

[0117] Example 5 Preparation of homogeneous enzyme immunoassay reagent for vanillylmandelic acid based on brominated derivatives

[0118] (1) Preparation of R1 reagent: 6.0% by mass of oxidized nicotinamide adenine dinucleotide, 6.0% of glucose-6-phosphate, 0.3% of bovine serum albumin, and 0.03% of NaN3 were dissolved in a 60 mmol / L Tris buffer at pH 7.8 to prepare a homogeneous enzyme substrate solution; then, anti-vanillylmandelic acid specific antibody was added to the homogeneous enzyme substrate solution and mixed to obtain R1 reagent, wherein the volume ratio of the anti-vanillylmandelic acid specific antibody to the homogeneous enzyme substrate solution was 1:625.

[0119] (2) Preparation of R2 reagent: 0.3% by mass of bovine serum albumin and 0.03% of NaN3 were dissolved in a Tris buffer solution with a concentration of 150 mmol / L and a pH of 8.0 to prepare R2 buffer, and then the vanillylmandelic acid bromide derivative enzyme-labeled conjugate was added to the R2 buffer solution and mixed to obtain R2 reagent. The volume ratio of the vanillylmandelic acid bromide derivative enzyme-labeled conjugate to the R2 buffer solution was 1:1250.

[0120] Example 6 ELISA detection of vanillylmandelic acid

[0121] 1. Preparation of ELISA standard curve for vanillylmandelic acid

[0122] (1) Preparation of standard samples

[0123] Vanillylmandelic acid powder (purchased from Sigma) was dissolved in methanol solution to prepare a 1 mg / mL stock solution. The stock solution was diluted with ELISA buffer to 80.00 ng / mL, 40.00 ng / mL, 20.00 ng / mL, 10.00 ng / mL, 5.00 ng / mL and 0.00 ng / mL standard solutions. The ELISA buffer contained 50 mmol / L Tris, 145 mmol / L NaCl and 0.25% BSA by mass.

[0124] (2) Preparation of standard curve using ELISA method for vanillylmandelic acid

[0125] The anti-vanillylmandelic acid antibody prepared in Example 3 was diluted with PBS to a final concentration of 1:10000, and 100 μL / well was coated on a 96-well ELISA plate and placed at 4°C for 12-24 h; the 96-well ELISA plate coated with the anti-vanillylmandelic acid antibody was washed 3 times with PBS, and 200 μL / well of 0.5% BSA solution was added, and the plate was blocked and placed at 4°C for 8-16 h. Then it was washed 3 times with PBS, and 20 μL / well of the standard was added. Then 100 μL / well of HRP-vanillylmandelic acid conjugate at a working concentration was added; after incubation at room temperature for 30 min, the plate was washed 5 times with PBS; then 100 μL of TMB substrate was added to each well, and incubated at room temperature for 30 min; then 100 μL of stop solution (2 mol / L sulfuric acid) was added to each well, and the absorbance at 450 nm was measured. Calibration was performed according to the absorbance at 450 nm corresponding to each standard, and a standard curve was prepared. The results are shown in the figure. Figure 1 shown.

[0126] 2. Detection of vanillylmandelic acid content in the sample to be tested

[0127] (1) Preparation of samples to be tested

[0128] Preparation method: Vanillylmandelic acid powder (purchased from Sigma) was dissolved in methanol solution to prepare a 1 mg / mL stock solution, and the stock solution was diluted in blank artificial urine to a final concentration of 0.00 ng / mL, 2.50 ng / mL, 15.00 ng / mL, and 75.00 ng / mL, respectively, to form blank, low, medium, and high concentration urine samples. Blank artificial urine is artificial urine without vanillylmandelic acid.

[0129] (2) Test method

[0130] The above-mentioned ELISA test method for vanillylmandelic acid was used to replace the standard with the above-mentioned blank, low, medium and high concentration urine samples, and the absorbance values ​​of the above-mentioned blank, low, medium and high concentration urine samples at 450nm were tested.

[0131] (3) Test results

[0132] Comparison Figure 1 The standard curve of the ELISA test of vanillylmandelic acid shown in the figure was used to calculate the content of vanillylmandelic acid in each sample, and 3 replicates were performed on each sample. The recovery rate was calculated based on the actual content of vanillylmandelic acid in the above samples. The results are shown in Table 1.

[0133] Table 1 ELISA test results of vanillylmandelic acid

[0134] Urine sample blank Low middle high Sample concentration (ng / mL) 0.00 2.50 15.00 75.00 Determination 1 0.00 2.51 15.19 76.25 Determination 2 0.00 2.55 14.96 75.07 Determination 3 0.00 2.56 15.05 74.83 Average value (ng / mL) 0.00 2.54 15.07 75.38 Recovery rate (%) - 101.6 100.5 100.5

[0135] From the results in Table 1, it can be seen that the recovery rates of vanillylmandelic acid in urine samples of different concentrations determined by the ELISA detection method of vanillylmandelic acid are all high, ranging from 100% to 102%, indicating that the anti-vanillylmandelic acid specific antibody prepared by the present invention fully meets the requirements for detecting trace vanillylmandelic acid content in samples, and the accuracy of the detection results is high.

[0136] Example 7 Homogeneous Enzyme Immunoassay for Vanillylmandelic Acid

[0137] 1. Create a standard curve

[0138] (1) Set the reaction parameters of Mindray BS480 fully automatic biochemical analyzer (Table 2).

[0139] (2) The operation steps are: first add R1 reagent, then add the standard, and finally add R2 reagent. After adding R2 reagent, measure the OD340 absorbance at different time points and calculate the reaction rate at different standard concentrations. In the actual operation process, the volume ratio of R1 reagent and R2 reagent needs to be adjusted continuously, and the light measuring point needs to be adjusted at the same time. Finally, a more ideal reaction standard curve is obtained, as shown below: Figure 1shown.

[0140] Table 2 Reaction parameters of Mindray BS480 fully automatic biochemical analyzer

[0141]

[0142] 2. Sample testing

[0143] The standard curve obtained by the vanillylmandelic acid homogeneous enzyme immunoassay reagent based on brominated derivatives of the present invention was used to repeatedly measure low, medium and high concentration quality control samples 10 times; the above-mentioned quality control samples were: the vanillylmandelic acid standard was dissolved in blank artificial urine to concentrations of 30.00 ng / mL, 150.00 ng / mL, and 300.00 ng / mL, respectively. The test results and data analysis are shown in Table 3.

[0144] Table 3 Sample measurement values ​​and evaluation of precision and recovery

[0145] Blood samples Low middle high Sample concentration (ng / mL) 30.00 150.00 300.00 1 30.33 152.67 307.28 2 31.54 151.83 297.41 3 30.79 145.97 310.55 4 30.85 153.08 296.57 5 29.51 154.81 305.08 6 31.00 152.37 312.29 7 30.77 148.57 299.00 8 30.20 149.05 308.51 9 31.62 155.22 311.34 10 29.68 150.60 298.89 Average value (ng / mL) 30.63 151.42 304.69 Standard Deviation (SD) 0.70 2.90 6.17 Precision (CV%) 2.29 1.92 2.03 Recovery rate (%) 102.10 100.95 101.56

[0146] The test results show that the vanillylmandelic acid homogeneous enzyme immunoassay reagent based on brominated derivatives prepared by the present invention has high accuracy in determining the trace content of vanillylmandelic acid in quality control samples, with a recovery rate between 100% and 103%; it has high precision, with CVs lower than 3%.

[0147] Example 8 Common hormone interference test

[0148] Thirty common hormones and hormone metabolites were selected as interfering substances for interference test. The concentration of interfering substances was adjusted to 10.00 ng / mL. The homogeneous enzyme immunoassay method of vanillylmandelic acid described in Example 7 was used for determination. The interfering substances to be tested were reacted with the R1 reagent prepared in Example 5, and then the R2 reagent was added. The OD of the above mixed solution was detected. 340 Absorbance value, according to Figure 2 The detection values ​​of the corresponding interfering substances were obtained. The names of 30 common hormones and hormone metabolites and the determination results are shown in Table 4.

[0149] Table 4 Results of common hormone interference tests

[0150] Serial number Interference Name Detection value (ng / mL) Serial number Interference Name Detection value (ng / mL) 1 Cortisol (Hydrocortisone) 0.00 2 Aldosterone 0.00 3 Androstenedione 0.00 4 Androsterone 0.00 5 Corticosterone 0.00 6 Corticosterone (cortisone) 0.00 7 Deoxycorticosterone 0.00 8 DHEA 0.00 9 Dehydroepiandrosterone Sulfate 0.00 10 Dihydrotestosterone 0.00 11 Estradiol 0.00 12 Estriol 0.00 13 Estrone 0.00 14 Cholesterol 0.00 15 17-Hydroxypregnenolone 0.00 16 17-Hydroxyprogesterone 0.00 17 Pregnenolone 0.00 18 Progesterone 0.00 19 Testosterone 0.00 20 Pregnanetriol 0.00 21 Pregnanediol 0.00 22 17α-Hydroxyprogesterone 0.00 23 Androstenedione 0.00 24 17-Ketosteroids 0.00 25 17-Hydroxycorticosteroids 0.00 26 Adrenaline 0.00 27 Norepinephrine 0.00 28 Dopamine 0.00 29 Homovanillic acid 0.00 30 Dihydroxymandelic acid 0.00

[0151] The test results show that the detection values ​​of the above 30 common hormones and hormone metabolites measured by homogeneous enzyme immunoassay of vanillylmandelic acid are all 0.00 ng / mL. It can be seen that the anti-vanillylmandelic acid specific antibody prepared by the present invention has strong specificity, can accurately identify and bind to vanillylmandelic acid, and has no cross reaction with common interferences.

[0152] Example 9 Comparative experiment of homogeneous enzyme immunoassay and high performance liquid chromatography for detecting vanillylmandelic acid

[0153] The homogeneous enzyme immunoassay method for vanillylmandelic acid described in Example 7 and the gold standard high performance liquid chromatography were used to measure 100 human urine samples, and correlation analysis was performed. The experimental data are shown in Table 5.

[0154] Table 5 Comparison of human urine sample test results

[0155] Sample No. Homogeneous enzyme immunoassay value (ng / mL) High performance liquid chromatography determination value (ng / mL) 1 140.35 139.78 2 162.04 168.53 3 51.33 51.43 4 24.30 25.00 5 131.52 126.25 6 117.60 119.65 7 143.11 148.74 8 175.49 170.12 9 72.42 75.39 10 20.50 21.03 11 64.80 66.45 12 59.23 59.20 13 103.71 100.96 14 25.63 25.20 15 39.75 38.56 16 151.62 160.34 17 115.89 116.77 18 134.56 131.56 19 148.00 151.71 20 47.30 46.05 21 215.12 219.44 22 188.52 186.78 23 160.11 160.94 24 124.52 124.52 25 317.77 331.00 26 80.27 81.09 27 65.93 64.18 28 28.44 29.05 29 161.32 159.66 30 175.58 180.09 31 117.98 118.24 32 173.32 176.30 33 111.04 113.33 34 90.58 91.52 35 81.52 81.55 36 34.60 33.67 37 182.96 175.84 38 170.45 170.99 39 226.23 220.32 40 135.21 141.07 41 29.65 29.66 42 68.10 69.42 43 100.81 99.97 44 51.32 51.68 45 75.62 77.05 46 201.63 200.84 47 150.32 153.29 48 183.07 180.82 49 85.56 86.00 50 177.52 172.25 51 91.96 92.00 52 35.00 35.12 53 121.78 121.11 54 148.53 150.20 55 170.03 168.05 56 20.00 20.15 57 254.30 250.30 58 105.77 105.62 59 81.45 80.61 60 107.95 109.93 61 143.12 144.80 62 311.68 320.73 63 222.64 220.53 64 155.63 157.36 65 83.40 83.95 66 137.68 139.81 67 122.59 123.30 68 106.31 108.03 69 46.82 46.79 70 156.19 160.55 71 32.32 32.43 72 64.90 65.16 73 158.85 156.67 74 170.09 169.93 75 114.53 115.28 76 100.07 101.32 77 56.83 56.94 78 157.97 158.81 79 233.88 239.70 80 304.50 289.99 81 265.91 260.86 82 170.19 173.45 83 210.73 211.01 84 172.86 175.37 85 32.50 32.63 86 49.81 50.01 87 89.67 89.24 88 105.23 103.34 89 24.93 25.09 90 118.65 119.56 91 77.25 78.51 92 53.61 54.86 93 180.79 184.52 94 41.22 41.46 95 125.92 129.22 96 26.66 26.67 97 63.43 64.10 98 175.90 169.93 99 167.86 169.27 100 56.08 56.56

[0156] Make a scatter plot of the above experimental data, see Figure 3 The linear equation obtained is: y = 1.0008x + 0.3399, and the correlation coefficient R 2 = 0.9975, indicating that the experimental data of human urine samples detected by the homogeneous enzyme immunoassay method of vanillylmandelic acid of the present invention and the gold standard high performance liquid chromatography method have high consistency, and the detection results are accurate and reliable.

[0157] Based on the above-mentioned ideal embodiments of the present invention, and through the above-mentioned description, relevant technicians can make various changes and modifications without departing from the technical concept of the present invention. The technical scope of the present invention is not limited to the contents of the specification, but must be determined according to the scope of the claims. Sequence Listing <110> Suzhou Boyuan Medical Technology Co., Ltd. <120> A homogeneous enzyme immunoassay reagent for vanillylmandelic acid based on brominated derivatives and a preparation method thereof <130> 2022.01.05 <160> 1 <170> SIPOSequenceListing 1.0 <210> 1 <211> 583 <212> PRT <213> Artificial Sequence <400> 1 Met Gly Ser Ala Ala Ser Leu Pro Pro Gln Ala Thr Gln Val Ser Phe 1 5 10 15 Ser Lys Ala Asp Phe Glu Glu Leu Leu His Val Val Asp Thr Ser Gln 20 25 30 Lys Asn Val Lys Glu Ala Leu Gly Lys Ala Gly Ile Ala Leu Gly Glu 35 40 45 Ala Pro Lys Gln Gln Pro Ala Pro Ser Ala Ala Ser Ile Cys Leu Glu 50 55 60 Gln Glu Ala Trp Arg Ser Gly Lys Leu Ser Val Thr Val Leu Gly Ala 65 70 75 80 Thr Gly Cys Leu Ala Lys Lys Glu Thr Phe Pro Ala Leu Leu Asp Leu 85 90 95 Phe Ala His Asp Tyr Leu Gln His Glu Ala Val Ile Val Cys Phe Ala 100 105 110 Arg Lys Ser Met Thr Thr Glu Asp Phe Arg Ala Tyr Leu Ser Glu Ala 115 120 125 Leu Ala Lys Ser His Val Cys Gln Cys Met Pro Glu Val Arg Asp Ser 130 135 140 Ile Pro Ala Phe Leu Lys Lys Val His Tyr Cys Ala Gly Ala Tyr Asp 145 150 155 160 Ser Val Glu Ala Met Thr Glu Leu Asp Lys Leu Leu Thr Val Glu Glu 165 170 175 Glu Arg Phe His Leu Asp Asp Asn Asp Ala Pro Lys Lys Gln Ser Phe 180 185 190 Arg Ile Phe Tyr Phe Ala Ile Pro Pro Phe Val Phe Gln Gly Ala Ala 195 200 205 Lys Ala Ile Lys Glu Val Ala Met Ala Lys Asp Gly Ser Thr Arg Leu 210 215 220 Ile Ile Glu Lys Pro Phe Gly His Asp Leu Thr Ser Ala Gln Glu Leu 225 230 235 240 Gln Glu Cys Leu Ser Ala Leu Phe Lys Glu Glu Glu Ile Tyr Arg Met 245 250 255 Asp His Phe Leu Gly Tyr Glu Ile Cys Gln Asn Ile Leu Ser Val Arg 260 265 270 Phe Gly Asn Gln Phe Leu Glu Pro Leu Met Asn Asn Lys His Val Ala 275 280 285 Ala Val Arg Val Thr Leu Lys Glu Cys Phe Gly Thr Glu Gly Arg Gly 290 295 300 Gly Tyr Phe Thr Lys Tyr Gly Ile Ile Arg Asp Val Ile Gln Asn His 305 310 315 320 Leu Leu Gln Met Leu Cys Leu Val Ala Met Glu Arg Pro Gly Asp Met 325 330 335 Asp Trp Glu Ala Asp Val Arg Asp Arg Lys Val Glu Leu Leu Lys Ala 340 345 350 Met Glu Pro Phe Asp Pro Ser Ser Val Val Leu Gly Gln Tyr Val Gly 355 360 365 Ala Lys Gly Lys Pro Gly Tyr Leu Glu Asp Asp Ser Ile Thr Glu Ala 370 375 380 Asp Arg Asp Met Ala Lys Lys Cys Pro Thr Phe Cys Gln Met Val Val 385 390 395 400 Arg Ile Asn Asn Glu Arg Trp Gln Cys Val Asn Phe Ile Val Arg Ala 405 410 415 Gly Lys Ala Ile Asp Glu Cys Lys Cys Glu Ile Arg Val Gln Phe Lys 420 425 430 Glu Ala Glu Cys Cys Gly Lys Leu Phe Gly Glu Gln Tyr Pro Ala Arg 435 440 445 Asn Glu Leu Val Leu Arg Val Ser Pro Gly Glu Ala Ile Tyr Met Lys 450 455 460 Met Ser Val Lys Ser Pro Gly Leu Ser Lys Gln Leu Met Gln Ser Glu 465 470 475 480 Met Asp Leu Ser Tyr Ser Val Arg Tyr Pro Gly Ile Tyr Cys Pro Ser 485 490 495 Ala Tyr Thr Arg Leu Ile Leu Ala Gly Ile Arg Gly Gln Ser Glu Ser 500 505 510 Phe Val Arg Cys Asp Glu Leu Met Arg Ser Trp Glu Leu Phe Thr Pro 515 520 525 Phe Leu Glu Lys Ile Ala Asp Trp Gln Pro Lys Pro Tyr Pro Tyr Gly 530 535 540 Ser Arg Gly Pro Ala Val Ala Cys Glu Ala Leu Glu Leu Tyr Gly Tyr 545 550 555 560 Gln Lys Pro Glu Gly Tyr Cys Trp Arg Pro Pro His Gln Pro Pro Ala 565 570 575 Leu Thr Arg Leu Met Thr Arg 580

Claims

1. A homogeneous enzyme immunoassay reagent for vanillylmandelic acid based on brominated derivatives, characterized in that: The method comprises an R1 reagent and an R2 reagent, wherein the R1 reagent comprises an anti-vanillylmandelic acid specific antibody and a homogeneous enzyme substrate solution; and the R2 reagent comprises a vanillylmandelic acid bromide derivative enzyme-labeled conjugate and an R2 buffer solution; The anti-vanillylmandelic acid specific antibody is produced by immunizing experimental animals with the vanillylmandelic acid bromide derivative immunogen, and the experimental animals are rabbits; The vanillylmandelic acid bromide derivative immunogen is formed by connecting the vanillylmandelic acid bromide derivative with a carrier, and its structural formula is shown in the following formula (I): Formula (I); The carrier is bovine serum albumin; The vanillylmandelic acid bromide derivative enzyme-labeled conjugate is formed by connecting the vanillylmandelic acid bromide derivative with artificially mutated glucose-6-phosphate dehydrogenase, and its structural formula is shown in the following formula (II): Formula (II); In the formula, mG6PDH is artificially mutated glucose-6-phosphate dehydrogenase, and the amino acid sequence of the artificially mutated glucose-6-phosphate dehydrogenase is SEQ ID NO: 1; The vanillylmandelic acid bromide derivative has a structural formula as shown in the following formula (III): Formula (III); The method for preparing the anti-vanillylmandelic acid specific antibody comprises the following steps: (S2.1) diluting the vanillylmandelic acid bromide derivative immunogen to 8.0 mg / ml with PBS buffer having a concentration of 10 mmol / L and a pH of 7.4 to obtain an artificial antigen solution, and then mixing 5.0 ml of the artificial antigen solution with an equal amount of Freund's complete adjuvant and injecting the solution into the experimental animals; (S2.2) One week later, the artificial antigen solution described in step (S2.1) was diluted by half with PBS buffer having a concentration of 10 mmol / L and a pH of 7.4, and then 5.0 ml of the diluted artificial antigen solution was mixed with an equal amount of Freund's incomplete adjuvant and injected into the above experimental animals; (S2.3) After that, the experimental animals are injected once every 4 weeks according to the method in step (S2.2), for a total of 5 injections, to strengthen immunity; (S2.4) Blood is collected from the experimental animals after booster immunization, and the blood is separated and purified to obtain anti-vanillylmandelic acid specific antibodies.

2. The homogeneous enzyme immunoassay reagent for vanillylmandelic acid based on brominated derivatives according to claim 1, characterized in that: The preparation method comprises the following steps: (S1.1) Preparation of R1 reagent: 6.0% by mass of oxidized nicotinamide adenine dinucleotide, 6.0% of glucose-6-phosphate, 0.3% of bovine serum albumin, and 0.03% of NaN3 are dissolved in a Tris buffer solution with a concentration of 60 mmol / L and a pH of 7.8 to prepare a homogeneous enzyme substrate solution; then, anti-vanillylmandelic acid specific antibody is added to the homogeneous enzyme substrate solution and mixed to obtain R1 reagent, wherein the volume ratio of the anti-vanillylmandelic acid specific antibody to the homogeneous enzyme substrate solution is 1:50 to 1:5000; (S1.2) Preparation of R2 reagent: 0.3% by mass of bovine serum albumin and 0.03% of NaN3 are dissolved in 150 mmol / L Tris buffer at pH 8.0 to prepare R2 buffer, and then the vanillylmandelic acid bromide derivative enzyme-labeled conjugate is added to the R2 buffer and mixed to obtain R2 reagent. The volume ratio of the vanillylmandelic acid bromide derivative enzyme-labeled conjugate to R2 buffer is 1:50 to 1:5000.

3. The homogeneous enzyme immunoassay reagent for vanillylmandelic acid based on brominated derivatives according to claim 2, characterized in that: The volume ratio of the anti-vanillylmandelic acid specific antibody to the homogeneous enzyme substrate solution is 1:625; the volume ratio of the vanillylmandelic acid bromide derivative enzyme-labeled conjugate to the R2 buffer is 1:1250.

4. The homogeneous enzyme immunoassay reagent for vanillylmandelic acid based on brominated derivatives according to claim 1, characterized in that: The method for preparing the vanillylmandelic acid bromide derivative immunogen comprises the following steps: (S3.1) dissolving 2.0% by mass of the carrier in 10.0 mmol / L sodium phosphate buffer at pH 8.0 to obtain a carrier solution; (S3.2) dissolving 1.0% by mass of the brominated vanillylmandelic acid derivative, 3.0% of dimethylformamide, and 3.0% of ethanol in 8.0 mmol / L potassium phosphate buffer at pH 7.5 to obtain a mixed solution, and stirring the mixed solution gently at 0 to 4° C. for 60 to 90 minutes to obtain a brominated vanillylmandelic acid derivative solution; (S3.3) The vanillylmandelic acid bromide derivative solution obtained in step (S3.2) is slowly added dropwise to the carrier solution obtained in step (S3.1), and then the reaction is stirred at 0-4°C for 12-24 hours to obtain a conjugate solution. 1.0 mmol / L ethylenediaminetetraacetic acid is added to the above conjugate solution, and then dialyzed and purified using 10.0 mmol / L HEPES buffer, pH=7.

0. The solution obtained after purification is the vanillylmandelic acid bromide derivative immunogen solution. 0.05% by mass of NaN3 is added to the above vanillylmandelic acid bromide derivative immunogen solution, and stored at -20°C.

5. The homogeneous enzyme immunoassay reagent for vanillylmandelic acid based on brominated derivatives according to claim 1, characterized in that: The preparation method of the vanillylmandelic acid bromide derivative enzyme-labeled conjugate comprises the following steps: (S4.1) Dissolve 200KU artificially induced glucose-6-phosphate dehydrogenase at a mass fraction of 5.0% in a sodium phosphate buffer containing 50.0 mmol / L and a pH of 7.3 at room temperature, then add 1.0 mmol / L ethylenediaminetetraacetic acid, mix well, and incubate at 4°C for 10 to 20 hours to obtain an artificially induced glucose-6-phosphate dehydrogenase solution; (S4.2) Dissolving 1.5% by mass of the brominated vanillylmandelic acid derivative, 4.5% of dimethylformamide, and 4.5% of ethanol in an 8.0 mmol / L potassium phosphate buffer solution at pH 7.5 to obtain a mixed solution, and stirring the mixed solution gently at 0 to 4° C. for 60 to 120 minutes to obtain a brominated vanillylmandelic acid derivative solution; (S4.3) The vanillylmandelic acid bromide derivative solution obtained in step (S4.2) is slowly added dropwise to the artificially induced glucose-6-phosphate dehydrogenase solution obtained in step (S4.1), and then the reaction is stirred at 0 to 4°C for 12 to 24 hours; the coupling product after the reaction is purified by a G-50 dextran gel chromatography column, and the solution obtained after purification is the vanillylmandelic acid bromide derivative enzyme-labeled conjugate solution, and 0.05% by mass of BSA and 0.05% by mass of NaN3 are added to the above-mentioned vanillylmandelic acid bromide derivative enzyme-labeled conjugate solution, and stored at 0 to 4°C.

6. The homogeneous enzyme immunoassay reagent for vanillylmandelic acid based on brominated derivatives according to claim 1, characterized in that: The synthetic route of the brominated vanillylmandelic acid derivative represented by formula (III) is as follows: 。

Citation Information

Patent Citations

  • Vanilmandelic acid immune detection reagent and preparation method thereof

    CN105175530A

  • Monoclonal antibodies to tacrolimus and immunoassay methods for tacrolimus

    US7078495B1